---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-208912"
form_type: "8-K"
ticker: "RXST"
cik: "0001111485"
company_name: "RxSight, Inc."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:31:33.743956+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# RxSight Reports Q1 2026 Sales of $30.9M, Net Loss Widens, Reiterates Full-Year Guidance

## Summary
- Q1 2026 sales of $30.9M, down 18.5% YoY, driven by 27,472 Light Adjustable Lens units sold.
- 20 Light Delivery Devices sold in Q1, expanding installed base to 1,154 units.
- Net loss of $(15.9)M ($(0.38)/share) vs $(8.2)M ($(0.20)/share) in Q1 2025.
- Cash, equivalents and short-term investments totaled $217.9M as of March 31, 2026.
- 2026 revenue guidance reiterated at $120M-$135M; gross margin 70%-72%.

## SEC filing metadata
- accession: 0001193125-26-208912
- form_type: 8-K
- ticker: RXST
- cik: 0001111485
- company_name: RxSight, Inc.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1111485/000119312526208912/0001193125-26-208912-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1111485/000119312526208912/rxst-20260506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-208912
- JSON: https://secwatch.observer/filing/0001193125-26-208912.json
- Plain text: https://secwatch.observer/filing/0001193125-26-208912.txt

## Source-grounded claims
- claim_id: 6dd1055b3af1be0506da6fb27d0b24193a054dcf
  claim: RxSight, Inc. reported the quarter ended March 31, 2026 results: revenue sales of $30.9 million, net income net loss of $(15.9) million, EPS $(0.38) per basic and diluted share. Guidance reaffirmed.
  evidence_excerpt: – May 6, 2026 – RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended March 31, 2026. Strategic Highlights and Recent Developments • Q1 sales of $30.9 million driven by 27,472 Light Adjustable Lens (LAL) units • 20 Light Delivery Devices (LDDs) sold in Q1, expanding the installed base to 1,154 units • Robust clinical data presented at
  evidence_url: https://www.sec.gov/Archives/edgar/data/1111485/000119312526208912/0001193125-26-208912-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.